Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)

The National Institute of Allergy and Infectious Diseases (NIAID) seeks a single awardee to lead a Clinical Research Network (CRN) focused on Antimicrobial Resistance (AMR). The CRN will consist of four coordinated centers—Scientific Leadership, Clinical Operations, Laboratory, and Statistics/Data Coordination—to design, implement, and manage multi‑site clinical trials (UM1 cooperative agreement) that address pivotal questions about new antibiotics, bacteriophage therapy, diagnostic tools, and optimal use of existing agents. The award is expected to fund roughly $15‑$18 million over the project period and will involve extensive data management, regulatory compliance, and collaboration with multiple clinical sites nationwide. Applicants must be eligible U.S. entities (for‑profit, nonprofit, government, tribal, etc.) and submit a comprehensive research plan, data‑sharing plan, and management structure. The award will be administered under a cooperative agreement, giving NIH substantial programmatic involvement. • Funding mechanism: UM1 Cooperative Agreement (complex‑structure research project) • Estimated total funding: $15‑$18 M (single award) • Key deliverables: establishment of four network centers, conduct of clinical trials on AMR, data coordination, and training of next‑generation researchers • Eligibility: U.S. public/private nonprofit, for‑profit, government, tribal entities (foreign entities not eligible) • Submission window: Oct 10 2026 – Nov 10 2026 (5 PM local time) • Award decision: July 1 2027; project start anticipated July 2027 • Reporting: annual RPPR, financial statements, final close‑out reporting